Martin Shkreli

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Martin Shkreli may face more securities fraud charges

Business By Damian Garde

Biotech bankruptcies, a trip to the Vatican, and Adam Feuerstein’s favorite bar

Pharmalot By Ed Silverman

Shkreli’s old company is sued for breaching sales contract for Daraprim

Heavyweights By Rebecca Robbins

Is Adam Feuerstein the most feared man in biotech?

Pharmalot By Ed Silverman

With Shkreli gone, drug maker vows to avoid ‘price gouging’

Pharmalot By Ed Silverman

A family-run drug maker faces tough choices to stay afloat in the Shkreli era

Politics By Dylan Scott

Drug sales dropped precipitously after Shkreli’s Turing hiked price, senator says

Business By Associated Press

Turing execs warned Martin Shkreli against price hike, lawyer says

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Senate committee holds hearing on drug prices

Pharmalot By Ed Silverman

FDA changes policy to prevent the next Martin Shkreli

Pharmalot By Ed Silverman

How much? AARP says drug prices greatly outpaced inflation in 2013

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Walgreens threatens to terminate Theranos partnership

Pharmalot By Ed Silverman

Pharma industry has more in common with Martin Shkreli than it likes to admit

Politics By Rebecca Robbins and Dylan Scott

Why Martin Shkreli reminds us so darn much of Donald Trump

Politics By David Nather

Officers at Martin Shkreli’s company received huge raises, documents show

Politics By David Nather

‘It’s not funny, Mr. Shkreli. People are dying.’

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Amgen releases ‘secret’ data, AstraZeneca forecasts dip in profits